Loading
A phase 2 trial of cemiplimab in lung cancer, run by Henry Ford Health System, not yet recruiting.
Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 is a phase 2, interventional study registered as NCT07450183 by Henry Ford Health System, with a registry enrolment figure of 33 participants, started 2027-01-01 and due to reach its primary completion in 2027-12-01. Interventions recorded: Cemiplimab; Adjuvant chemotherapy. Conditions listed: Lung Cancer (NSCLC). Primary outcome: Pathologic Complete Response Rate. Lung eligibility wording from the registry: "* Patient diagnosed with early-stage resectable stage II to IIIA squamous or non-squamous, operable treatment naïve NSCLC with PD-L1 TPS ≥50%". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Regeneron, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.